Withdrawal syndrome following cessation of antihypertensive drug therapy

  title={Withdrawal syndrome following cessation of antihypertensive drug therapy},
  author={George N. Karachalios and Alexandros Charalabopoulos and Vicky Papalimneou and D. N. Kiortsis and P Dimicco and O. K. Kostoula and K. Charalabopoulos},
  journal={International Journal of Clinical Practice},
In this study, a review of the available information concerning abrupt withdrawal of antihypertensive drug therapy is presented. Abrupt withdrawal of these drugs can produce a syndrome of sympathetic overactivity that includes nervousness, tachycardia, headache, agitation and nausea 36–72 h after cessation of the drug. A withdrawal syndrome may occur after discontinuation of almost all types of antihypertensive drugs, but mostly occurs with clonidine, β‐blockers, methyldopa and guanabenz. Less… 

Antihypertensive withdrawal for the prevention of cognitive decline.

The effects of complete withdrawal of at least one antihypertensive medication on incidence of dementia, cognitive function, blood pressure and other safety outcomes in cognitively intact and cognitive impaired adults is assessed.

Headache: one of the most common and troublesome adverse reactions to drugs.

  • A. Ferrari
  • Medicine, Psychology
    Current drug safety
  • 2006
The classes of drugs which induce headache are described, the frequency of headache induction among the drugs of the same class is analyzed, and the possible mechanisms underlying headache induction are discussed.

Clonidine withdrawal induced sympathetic surge

A 30-year-old man with a history of epilepsy and substance misuse presented to the hospital with status epilepticus. Difficult seizure control necessitated anaesthetising the patient followed by

Management of renin-angiotensin-aldosterone inhibitors and other antihypertensives and their clinical effects on pre-anesthesia blood pressure

The study shows that RAASI cannot provide optimal pre-anesthesia blood pressure and lead to an increase in the number of postponed surgeries, probably due to withdrawal of medication before the operation.

Dexmedetomidine for opioid and benzodiazepine withdrawal in pediatric patients.

  • A. OschmanTara McCabeR. Kuhn
  • Medicine
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2011
A limited body of published evidence from retrospective studies and case reports suggests a potential role for dexmedetomidine as an adjunct therapy to provide sedation and analgesia to reduce narcotic withdrawal symptoms in pediatric patients.

Management of Acute Hypertensive Response in Patients With Ischemic Stroke

Based on the potential deleterious effect of lowering BP observed in some clinical trials in patients with acute ischemic stroke and because of the lack of convincing evidence to support acute BP lowering in those situations, aggressive BP reduction in patients presenting with acute Ischemic Stroke is currently not recommended.

[Perioperative medication management].

The aim of this article is to provide a summary of the existing evidence concerning perioperative medication in patients undergoing non-cardiac surgery.

Management of Blood Pressure during Acute Stroke: A Narrative Review

Injectable labetalol, nicardipine, hydralinzine, and enalaprilat are considered appropriate for acute management of elevated BP in patients with acute ischemic stroke and their BP levels should be lowered aggressively using intravenous infusion along with frequent monitoring.

New antihypertensive medications and clinical implications.




Withdrawal Syndrome Following Cessation of Guanabenz Therapy

It is concluded that guanabenz therapy should not be discontinued abruptly and that, when possible, the dosage should be limited to less than 48 mg/day.

Factors influencing the success of withdrawal of antihypertensive drug therapy.

The possibility that echocardiography may indicate the likelihood of a rapid return to hypertension when drug therapy is ceased is raised, and predictive effects of left ventricular hypertrophy and duration of therapy on rate of redevelopment of hypertension are demonstrated.

Withdrawal of antihypertensive therapy. Hypertensive crisis in renovascular hypertension.

It is concluded that rebound hypertension may follow gradual as well as abrupt reduction of clonidine dosage, and that patients with renovascular hypertension may be at greatest risk.

Clonidine withdrawal. Mechanism and frequency of rebound hypertension.

It is concluded that the clonidine withdrawal phenomenon is a frequently occurring and potentially dangerous syndrome and overactivity of the sympathetic nervous system is mainly responsible, without the mediation of the renin angiotensin system.

The syndrome associated with the withdrawal of beta-adrenergic receptor blocking drugs.

It is observed that patients with angina pectoris who were taking part in a multidose study of propranolol in angina experienced a higher incidence of chest pains during the first week of placebo compared with the second week (Prichard & Gillam, 1971).

Blood pressure and heart rate and withdrawal of antihypertensive drugs.

Methyldopa and, especially, beta-blocking drugs are less likely to produce withdrawal reactions than clonidine or the postganglionic neurone- blocking drugs, and patients taking these drugs are therefore more likely to suffer violent reactions if they forget to take their tablets.

Abrupt and gradual change from clonidine to beta blockers in hypertension.

Halving the previous daily clonidine dose and discontinuing it after three days on concomitant treatment with atenolol or timolol in increasing doses proved successful and caused only few side-effects in 14 hypertensive inpatients.

Catecholamine metabolism during clonidine withdrawal

These findings are consistent with augmented catecholamine release and central noradrenergic activation which may produce psychopathology in some psychiatric patients during clonidine withdrawal.